Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide

Figure 11

The expression levels of caspase-3 were declined remarkably both in spinal cord (a) and cerebral cortex (b) by late C16 application compared with the vehicle control, evaluated by Western blotting analysis. The levels of caspase-3 expression were evidently decreased both in spinal cord (c) and cerebral cortex (d) by medium to high-dose C16 treatment at week 2 post-immunization. Caspase-3 expression levels were evidently decreased both in spinal cord (e) and cerebral cortex (f) by medium to high-dose C16 treatment at week 8 after immunization. (g) The levels of caspase-3 expression were suppressed by late treated C16 treatment to a certain extent, revealed by Western blotting analysis: ^a𝑃<0.05 versus normal rats, ^b𝑃<0.05 versus vehicle control rats, ^c𝑃<0.05 versus C16 treated EAE rats at week 2 postimmunization group; ^d𝑃<0.05 versus vehicle control rats at week 8 after immunization. (h) The levels of caspase-3 expression were reduced by medium to high-dose C16 treatment at week 2 after immunization (i) The levels of caspase-3 expression were reduced by medium to high-dose C16 treatment at week 8 after immunization: ^a𝑃<0.05 versus normal rats and ^b𝑃<0.05 versus vehicle control rats; ^c𝑃<0.05 versus 0.5 mg/per day C16 treated EAE rats, ^d𝑃<0.05 versus 1 mg/per day C16 treated EAE rats.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)